36 completed. 36 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 36 | Completed 36 |
| Phase 2 | 2 | Completed 2 |
Follow Measles: new trials by email Literature Review of Measles trials Research Report on Measles
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months SIBP MMR Vaccine, GSK MMR Vaccine (PRIORIX), Yellow Fever Vaccine (Stamaril) - Measles-Mumps-Rubella | Phase 3 | Completed | Shanghai Institute Of Biological Products | 1200 | 2024-06-28 | 2026-01-08 |
| Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Measles-Rubella vaccine Bio Farma, MR Vaccine SII - Congenital Rubella Infection, Measles | Phase 2 / Phase 3 | Completed | PT Bio Farma | 540 | 2019-09-03 | 2019-12-04 |
| Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Measles and Rubella vaccine, Measles, Mumps and Rubella vaccine - Rubella, Measles | Phase 2 / Phase 3 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 432 | 2018-11-20 | 2020-08-13 |
| Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. MMR Bio-Manguinhos, MMR GlaxoSmithKline - Measles, Mumps | Phase 3 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 1560 | 2015-02-01 | 2016-07-11 |
| Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Priorix, M-M-R II, Varivax - Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine | Phase 3 | Completed | GlaxoSmithKline | 1742 | 2014-08-25 | 2021-01-07 |
| Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Priorix®, Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine - Rubella, Mumps | Phase 3 | Completed | GlaxoSmithKline | 996 | 2014-07-01 | 2018-06-06 |
| Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Priorix, M-M-R II, Varivax - Rubella, Measles | Phase 3 | Completed | GlaxoSmithKline | 5016 | 2012-11-09 | 2019-11-25 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Priorix, M-M-R II, Varivax - Measles, Mumps | Phase 3 | Completed | GlaxoSmithKline | 4538 | 2012-10-10 | 2021-01-07 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Priorix, M-M-R II, Kinrix - Measles-Mumps-Rubella | Phase 3 | Completed | GlaxoSmithKline | 4011 | 2012-06-21 | 2019-11-25 |
| Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) MMRV (AMP), MMRV (2006 process) - Measles, Mumps | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1412 | 2012-06-05 | 2018-10-31 |
| Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children PriorixTetra™, Meningitec - Rubella, Varicella | Phase 3 | Completed | GlaxoSmithKline | 716 | 2012-02-06 | 2018-08-17 |
| Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus - Tetanus, Diphtheria | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 3372 | 2011-04-01 | 2015-06-03 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus - Japanese Encephalitis, Measles | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 542 | 2010-08-01 | 2014-08-15 |
| Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™ - Varicella, Rubella | Phase 3 | Completed | GlaxoSmithKline | 450 | 2009-11-09 | 2018-06-08 |
| Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 PriorixTM, VarilrixTM, Priorix-Tetra® - Measles, Varicella | Phase 3 | Completed | GlaxoSmithKline | 475 | 2008-10-01 | 2018-06-08 |
| Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers MenACWY-CRM + MMRV, MMRV, MenACWY-CRM - Meningococcal Infections | Phase 3 | Completed | Novartis Vaccines | 1630 | 2008-02-01 | 2013-04-19 |
| Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) ProQuad® manufactured with recombinant Human Albumin (rHA) - Measles, Mumps | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1620 | 2007-11-29 | 2018-01-30 |
| Safety Study of ProQuad® rHA in Infants (V221-037) ProQuad® - Measles, Mumps | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3388 | 2007-10-24 | 2017-10-17 |
| Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV) - Meningococcal Meningitis, Measles | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1378 | 2007-05-01 | 2016-05-16 |
| Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) ProQuad®, Infanrix® hexa - Varicella, Measles | Phase 3 | Completed | Merck Sharp & Dohme LLC | 955 | 2007-01-12 | 2018-03-19 |
Showing 20 of 36. Sign in to see all of them.
Rubella (33) · Mumps (32) · Chickenpox (25) · Haemophilus Infections (4) · Meningitis, Meningococcal (3) · Diphtheria (2) · Poliomyelitis (2) · Tetanus (2) · Whooping Cough (2) · Encephalitis, Japanese (1) · Hepatitis B (1) · Meningitis (1) · Meningococcal Infections (1) · Pneumonia (1)
Infections (36) · Mononegavirales Infections (36) · Morbillivirus Infections (36) · Paramyxoviridae Infections (36) · RNA Virus Infections (36) · Virus Diseases (36) · Rubivirus Infections (33) · Togaviridae Infections (33) · Mouth Diseases (32) · Parotid Diseases (32) · Parotitis (32) · Rubulavirus Infections (32) · Salivary Gland Diseases (32) · Stomatognathic Diseases (32) · DNA Virus Infections (25)
measles, mumps, rubella, varicella vaccine (15) · Measles-Mumps-Rubella Vaccine (9) · Chickenpox Vaccine (5) · Rubella Vaccine (5) · Hepatitis A Vaccines (4) · 13-valent pneumococcal vaccine (3) · Meningococcal Vaccines (3) · CRM197 (non-toxic variant of diphtheria toxin) (2) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Vaccines, Attenuated (2) · Adenosine Monophosphate (1) · DTPP vaccine (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Duration of Therapy (1) · Herpes Zoster Vaccine (1)
Merck Sharp & Dohme LLC (13) · GlaxoSmithKline (12) · Sanofi Pasteur, a Sanofi Company (5) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (2) · Bandim Health Project (1) · Novartis Vaccines (1) · PT Bio Farma (1) · Shanghai Institute Of Biological Products (1)
United States (10) · Germany (6) · Puerto Rico (5) · Estonia (3) · Finland (3) · Taiwan (3) · Brazil (2) · Italy (2) · South Korea (2) · Spain (2) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · France (1)
Anne Fiquet, MD (1) · Eliane Matos Santos (1) · Kleber G Luz, PhD (1) · Walter Otieno, Doctor (1)
PMID 16452343, PMID 16567978, PMID 16804432, PMID 17060336, PMID 17502347, PMID 19366435, PMID 22123890, PMID 22406278, PMID 22772170, PMID 25765966, PMID 26362659, PMID 27149048, PMID 27423382, PMID 27879555, PMID 29902133, PMID 30481110